About Fusion Pharma
Fusion Pharma is a Healthcare company based in Hamilton (Canada) founded in 2014, and was acquired by Astrazeneca in March 2024. Targeted alpha therapeutics for cancer treatment are developed. It operates on a HealthTech model. Fusion Pharma has raised $170.92 million across 4 funding rounds from investors including Astrazeneca, Varian and TPG. Fusion Pharma offers products and services including Targeted Alpha Therapeutics and Fast-Clearâ„¢ Technology. Its focus areas include Biotechnology and Radiopharmaceuticals.
Company details
Fusion Pharma is engaged in the development of next-generation radiopharmaceuticals for precision medicine, specifically targeting cancer through targeted alpha therapeutics. The company utilizes alpha-emitting medical isotopes connected to molecules that selectively target cancer cell biomarkers, causing lethal DNA breaks with minimal impact on surrounding healthy tissue. Their proprietary Fast-Clear technology is designed to enhance safety by clearing drugs from healthy tissues. Operating in the healthcare and biotechnology sector, Fusion Pharma also emphasizes robust supply chain management and manufacturing expertise to support global market needs, stemming from their origins as a spin-out of the Centre for Probe Development and Commercialization (CPDC).
- Headquarters Hamilton, Canada
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website fusionpharma.com
- Social LinkedIn X
- Acquired by Astrazeneca (Mar 2024)
- Annual Revenue$2.07 M (USD)42as on Dec 31, 2023
- Net Profit-$94.9 M (USD)-8as on Dec 31, 2023
- EBITDA-$99.23 M (USD)-13as on Dec 31, 2023
- Total Equity Funding$170.92M (USD)
in 4 rounds
- Latest Funding Round$19.92M (USD), Series B
Jan 2020
- InvestorsAstrazeneca
& 13 more
- Acquired byAstrazeneca
(Mar 2024)
Products & Services of Fusion Pharma
Fusion Pharma offers a comprehensive portfolio of products and services, including Targeted Alpha Therapeutics and Fast-Clear™ Technology.
Alpha particles are used to kill cancer cells selectively.
Linker technology is designed to enhance drug safety profile.
Funding Insights of Fusion Pharma
Fusion Pharma has successfully raised a total of $170.92M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $19.92 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $170.92M
- Total Rounds 4
- Last Round Series B — $19.92M
- First Round $25M
(Feb 2017)
- Investors Count 13
All 4 funding rounds of Fusion Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2020 | $19.92M | Series B | – | CPP Investments | – |
| Apr 2019 | $105M | Series B | – | Varian Medical Systems, Orbimed | |
| Sep 2017 | $21M | Series A | – | Adams Street Partners, Seroba Life Sciences | – |
| Feb 2017 | $25M | Series A | – | Johnson & Johnson Innovation |
14 investors in total: 14 institutional.
Investors in Fusion Pharma
Fusion Pharma has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include Astrazeneca, Varian and TPG.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Private markets investment management with strategies in equity, credit, and secondary investments. | adamsstreetpartners.com | |||
Early-stage life sciences companies are supported through venture capital investments. | genesyscapital.com | Toronto, Canada | ||
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
| healthcap.eu | ||||
Fund of funds focused on pre-seed and seed-stage companies | 1992 | tpg.com | Fort Worth, United States | |
Pension fund assets are managed for sustainable long-term growth. | 1997 | cppinvestments.com | Toronto, Canada | |
Varian is focused on developing cancer treatment technologies. | 1948 | varian.com | Palo Alto, United States | |
| jnjinnovation.com |
Investor details for Fusion Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Fusion Pharma
43 people are tracked at Fusion Pharma (18 in leadership, 7 in board & advisors, 18 in team).
| Name | Role | Group |
|---|---|---|
Ken Baker | Vice President Of Manufacturing And Development | Leadership |
Luis Miguel Esteves | Associate Director Of Manufacturing | Leadership |
Lan B. | Senior Director | Leadership |
Aimen Zlitni | Director, R&d Strategy │ Global Program Lead | Leadership |
A.omer Nawaz | Vice President, Head Of Radiation Science And Molecular Imaging | Leadership |
Catherine B. | Sr. Dir. Safety & Phamracoviglance, Head Of Safety | Leadership |
Dmitri Bobilev | Chief Medical Officer | Leadership |
John Valliant | CEO | Leadership |
Eric Burak | CTO | Leadership |
Gowri Raghunandan | Director, Technical Operations | Leadership |
Brigitte Thériault | Director, Biology | Leadership |
Christopher Leamon | Chief Scientific Officer | Leadership |
Chris Baltrunas | Director, IT Operations | Leadership |
Sheila Walsh Daly | Vice President Human Resources | Leadership |
Stephanie Allan | Director, Clinical Scientist | Leadership |
Vicki Toner | Director, External Radiopharmaceutical Manufacturing Operations | Leadership |
Stuart Mahoney | Director Of Chemistry | Leadership |
Lorraine Hughes | Vice President Clinical Operations | Leadership |
Oliver Sartor | Advisor | Board & advisors |
Geoffrey Shapiro | Advisor | Board & advisors |
23 more people are available in the full profile.
Complete people profiles for Fusion Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Fusion Pharma
5 dated milestones of Fusion Pharma across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Fusion Pharma is founded.
- Funding First funding round of $25.0M.
- Funding Latest funding round, Series B, of $19.9M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Astrazeneca.
Web traffic of Fusion Pharma
The website of Fusion Pharma (fusionpharma.com) receives about 3.8K visits a month and ranks #4,193,351 among all websites worldwide, #5,182 in Biotechnology and Pharmaceuticals.
- Monthly visits3.8K
▼ 11.4% vs previous month
- Unique visitors1.8K
per month
- Global rank#4,193,351
among all websites
- Category rank#5,182
Health · Biotechnology and Pharmaceuticals
- Bounce rate35%
- Pages per visit1.7
- Average visit50 sec
- DevicesDesktop 27% · Mobile 73%
Websites whose visitors overlap most with Fusion Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| fredhutch.org | 100% | 484.8K | #100,633 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Fusion Pharma
Complete news archive for Fusion Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Fusion Pharma
Fusion Pharma was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Fusion Pharma is headquartered in Hamilton, Canada. It is registered at Hamilton, Ontario, Canada.
Fusion Pharma is a funded company, having raised a total of $170.92M across 4 funding rounds to date. The company's 1st funding round was a Series A of $25M, raised on Feb 2017.
Annual revenue of Fusion Pharma is $2.07M as on Dec 31, 2023.
Fusion Pharma is engaged in the development of next-generation radiopharmaceuticals for precision medicine, specifically targeting cancer through targeted alpha therapeutics. The company utilizes alpha-emitting medical isotopes connected to molecules that selectively target cancer cell biomarkers, causing lethal DNA breaks with minimal impact on surrounding healthy tissue. Their proprietary Fast-Clear technology is designed to enhance safety by clearing drugs from healthy tissues. Operating in the healthcare and biotechnology sector, Fusion Pharma also emphasizes robust supply chain management and manufacturing expertise to support global market needs, stemming from their origins as a spin-out of the Centre for Probe Development and Commercialization (CPDC).
Fusion Pharma offers Targeted Alpha Therapeutics and Fast-Clearâ„¢ Technology.
Fusion Pharma has 14 investors. Key investors include Astrazeneca, Varian, TPG, Orbimed, and CPP Investments.
Yes. Fusion Pharma was acquired by Astrazeneca in March 2024.